文献速递新生儿儿童呼吸儿童内分泌与遗传代谢

美国2015-2020年儿科临床试验数量与儿童疾病负担的对比

Pediatric National Institutes of Health and Industry-Funded Clinical Trials Versus Pediatric Burden of Disease: United States, 2015-2020.
PubMed 文献 · J Pediatr · 2025-03-03

该横断面研究评估了2015至2020年美国工业界与NIH资助的儿科临床试验启动数量与儿童疾病负担(死亡、DALYs、寿命损失年、残疾生存年)的关联。结果显示,DALYs最高的20类疾病占总DALYs的79.4%,但仅占工业界资助试验的43.5%和NIH资助试验的41.9%;工业界试验与DALYs的Spearman相关系数为0.59,NIH为0.44。新生儿疾病、先天畸形和哮喘是双方均优先度较低的高负担类别。

要点

  • DALYs最高的20类疾病占总DALYs的79.4%,却仅覆盖43.5%的工业界试验和41.9%的NIH试验。
  • 工业界试验与DALYs的关联(rs=0.59)强于NIH试验(rs=0.44)。
  • 新生儿疾病、先天畸形和哮喘是工业界与NIH均优先度最低的高负担类别。

核心结论

  • 美国工业界和NIH资助的儿科临床试验与儿童疾病负担的关联因负担指标而异,部分高负担疾病被低估。

研究设计与样本

  • 横断面研究,评估2015至2020年美国工业界或NIH资助的启动临床试验与儿科疾病负担的关联。
  • 疾病负担以死亡、残疾调整生命年(DALYs)、寿命损失年和残疾生存年衡量。

主要发现

  • 2015至2020年,工业界资助启动3047项临床试验,NIH资助启动1480项临床试验。
  • DALYs最高的20类疾病占总DALYs的79.4%,占工业界资助试验的43.5%和NIH资助试验的41.9%。
  • 工业界试验与DALYs的Spearman秩相关系数rs=0.59,NIH试验为rs=0.44。
  • 以死亡、寿命损失年和残疾生存年衡量的疾病负担与试验启动的相关系数rs值范围为0.18至0.48。
  • 工业界和NIH均优先度最低的高负担疾病类别为新生儿疾病、先天畸形和哮喘。

临床怎么用

  • 儿科医生可关注被低估的高负担疾病领域(如新生儿疾病、先天畸形、哮喘)的临床试验机会。
  • 了解工业界与NIH资助试验的分布差异,有助于为患者寻找合适的临床研究资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate how the number of pediatric clinical trials, as a proxy for industry and National Institutes of Health (NIH) research priorities, compared with population-level burden of childhood disease in the United States. STUDY DESIGN: Cross-sectional study evaluating associations between initiated clinical trials funded by industry or the NIH and pediatric burden of disease in the US. Disease burden was measured as deaths, disability-adjusted life-years (DALYs), years of life lost, and years lived with disability. RESULTS: From 2015 through 2020, 3047 clinical trials were initiated with industry funding, compared with 1480 clinical trials initiated with NIH funding. The leading 20 disease categories with the greatest burden of disease by DALYs accounted for 79.4% of total DALYs; these 20 categories were the focus of 43.5% of all industry-funded trials and 41.9% of NIH-funded trials during the study period. Industry-sponsored pediatric clinical trials had a moderately strong monotonic relationship with DALYs (Spearman rank order coefficient [rs] = 0.59), compared with rs = 0.44 for NIH-funded clinical trials. Disease burden as measured by deaths, years of life lost, and years lived with disability demonstrated a broad range of correlations with clinical trial initiation, with rs values ranging from 0.18 to 0.48. The least prioritized high-burden disease categories by both industry and NIH were neonatal disorders, congenital birth defects, and asthma. CONCLUSIONS: Industry-sponsored and government-funded pediatric clinical trials in the US are variably associated with pediatric disease burden across measures of disability and mortality. Underprioritized pediatric diseases with significant burden of disease deserve special consideration for clinical trials through future legislative attention and corresponding funding.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Goyal A, Chang CL, Zdanowicz Z, et al. Pediatric National Institutes of Health and Industry-Funded Clinical Trials Versus Pediatric Burden of Disease: United States, 2015-2020. J Pediatr. 2025. PMID: 40044028. doi:10.1016/j.jpeds.2025.114525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。